Q3 FY2026 · ended Sep 30, 2026 · Revenue $1.02B, +32.0% YoY · Filed Nov 3, 2026
BioMarin Pharmaceutical Inc (BMRN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $1.0 billion and a net loss of $122.8 million. Free cash flow was $159.9 million. As of Sep 30, 2026 it held $736.0 million in cash and investments and $4.2 billion in total debt.
Revenue
$1.02B
+32.0% vs year-ago quarter
Net income
$-122.83M
-299.5% vs year-ago quarter
Operating cash flow
$188.21M
-48.9% vs year-ago quarter
Free cash flow
$159.92M
-53.0% vs year-ago quarter
EPS
$-0.63
-293.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
193.69M
+0.8% vs year-ago quarter
Net cash
$-3.44B
Q3 FY2026
Operating margin
3.1%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BMRN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Novato, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1048477
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.0B | $989.7M | $766.2M | $874.6M | $776.1M |
| Operating income | -$82.1M | $110.9M | $129.6M | -$44.6M | -$46.7M |
| Net income | -$122.8M | $44.8M | $105.5M | -$46.6M | -$30.7M |
| Diluted EPS | -$0.63 | $0.23 | $0.54 | -$0.23 | -$0.16 |
| Operating cash flow | $188.2M | $168.1M | $220.7M | $99.6M | $368.7M |
| Free cash flow | $159.9M | $139.3M | $199.7M | $58.9M | $340.2M |
| Total assets | $11.6B | $11.7B | $8.6B | $7.6B | $7.6B |
| Total liabilities | $5.3B | $5.4B | $2.4B | $1.5B | $1.6B |
| Stockholders' equity | $6.3B | $6.3B | $6.2B | $6.1B | $6.1B |
| Cash and investments | $736.0M | $874.0M | $2.2B | $2.1B | $2.0B |
| Total debt | $4.2B | $4.2B | $1.4B | $45.7M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 2, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 6, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 30, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Other events
|
Sep 15, 2026 | Sep 15, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 14, 2026 | Sep 10, 2026 |
All 1000 BioMarin Pharmaceutical Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.